A phase I study (investigator-initiated) on the safety and pharmacokinetics of Bortezomib with combination chemotherapy in pediatric and young adult patients with refractory acute lymphocytic leukemia

Trial Profile

A phase I study (investigator-initiated) on the safety and pharmacokinetics of Bortezomib with combination chemotherapy in pediatric and young adult patients with refractory acute lymphocytic leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms BZM-ALL-1
  • Most Recent Events

    • 17 Dec 2015 Planned End Date changed from 31 Dec 2015 to 31 Mar 2016 as reported by University Hospital Medical Information Network - Japan record.
    • 07 Apr 2015 Planned End Date changed from 30 Jun 2015 to 31 Dec 2015 as reported by University Hospital Medical Information Network - Japan record.
    • 24 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top